<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168311</url>
  </required_header>
  <id_info>
    <org_study_id>81/02</org_study_id>
    <nct_id>NCT00168311</nct_id>
  </id_info>
  <brief_title>A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia</brief_title>
  <acronym>rTMS</acronym>
  <official_title>A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magentic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia and Related Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Alfred</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is pilot data to suggest the therapeutic value of rTMS applied to the left prefrontal
      cortex in the treatment of negative symptoms. Neuroimaging studies demonstrate abnormal
      activity in this region in patients experiencing negative symptoms. Finally rTMS applied at
      high frequency shows the capacity to up-regulate cortical activity in a way that would
      provide an explanation for a therapeutic response.

      The study involves participants receiving 15 sessions of high frequency rTMS treatment
      applied bilaterally to the prefrontal cortex over a 3 week period or sham rTMS. Following
      this double blind phase, participants randomised to placebo treatment will be offered 15
      sessions of active treatment.

      In addition, ppTMS (paired pulse TMS) will be conducted prior to the onset of treatment and
      after completion of the course, as a means of measuring cortical inhibition and facilitation.
      NIRS (Near Infra red spectroscopy) will also be conducted prior to, during and after the
      first and last treatment sessions to allow monitoring of oxygenated and deoxygenated
      haemoglobin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main outcome measure used is the SANS (Scale for the Assessment of Negative Symptoms.
      This is a semi strucutured interview which provides scores from 0-70. This is administered at
      baseline, week 2, 3, 5 and 6.

      Other outcome measures administered are (frequency mentioned above): PANSS (Positive and
      Negative Syndrome Scale) and the Calgery Depression Scale for Schizophrenia, A cognitive
      battery is also administered.

      Inclusion Criteria:

        -  Diagnostic and Statistical Manual-IV diagnosis of schizophrenia or schizoaffective
           disorder, age over 18

        -  Persistent negative symptoms of moderate to severe intensity

        -  Failure to respond to a minimum of two antipsychotic medications

        -  No increase or initiation of new antipsychotic therapy in the four weeks prior to
           entering the trial Exclusion Criteria

        -  Prominent positive symptoms

        -  Have an unstable medical condition, neurological disorder or any history of seizure
           disorder or are currently pregnant or lactating

        -  Previous brain injury or surgery, any metal clips, plates or other metal items in the
           head, cardiac pacemaker

        -  Subjects at high risk of violence or suicide as determined by the investigator and
           treating clinicians

        -  Substance dependence
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for the Asessment of Negative Symptoms (SANS)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Scale for Assessment of Negative Symptoms [SANS]. This is a semi structured interview. Assessments are conducted on a six-point scale (0=not at all to 5=severe)with a total score range of 0-70. A score of &gt;50 is considered to be a moderate-severe intensity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral high frequency (10 Hertz) rTMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Bilateral Sham rTMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation</intervention_name>
    <description>Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.</description>
    <arm_group_label>Active Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham TMS</intervention_name>
    <arm_group_label>Sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of schizophrenia or schizoaffective disorder, age over 18

          -  Persistent negative symptoms of moderate to severe intensity

          -  Failure to respond to a minimum of two antipsychotic medications

          -  No increase or initiation of new antipsychotic therapy in the four weeks prior to
             entering the trial

        Exclusion Criteria:

          -  Prominent positive symptoms

          -  Have an unstable medical condition, neurological disorder or any history of seizure
             disorder or are currently pregnant or lactating

          -  Previous brain injury or surgery, any metal clips, plates or other metal items in the
             head, cardiac pacemaker

          -  Subjects at high risk of violence or suicide as determined by the investigator and
             treating clinicians

          -  Substance dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul B Fitzgerald, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alfred Psychiatry Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>June 15, 2010</results_first_submitted>
  <results_first_submitted_qc>April 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2012</results_first_posted>
  <last_update_submitted>April 15, 2012</last_update_submitted>
  <last_update_submitted_qc>April 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Alfred</investigator_affiliation>
    <investigator_full_name>Assoc Professor Paul Fitzgerald</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Negative Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 20 patients were randomly assigned. Patients were recruited from the outpatient department of two public area mental health services and by referral from a number of private psychiatrists between January 2003 and July 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Treatment</title>
          <description>Bilateral high frequency (10Hz) rTMS</description>
        </group>
        <group group_id="P2">
          <title>Sham Treatment</title>
          <description>Sham bilateral rTMS treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Treatment</title>
          <description>Bilateral high frequency (10Hz) rTMS</description>
        </group>
        <group group_id="B2">
          <title>Sham Treatment</title>
          <description>Sham bilateral rTMS treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>16 men and 4 women</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Scale for the Asessment of Negative Symptoms (SANS)</title>
        <description>Scale for Assessment of Negative Symptoms [SANS]. This is a semi structured interview. Assessments are conducted on a six-point scale (0=not at all to 5=severe)with a total score range of 0-70. A score of &gt;50 is considered to be a moderate-severe intensity.</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Bilateral high frequency (10Hz) rTMS</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Sham bilateral rTMS treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for the Asessment of Negative Symptoms (SANS)</title>
          <description>Scale for Assessment of Negative Symptoms [SANS]. This is a semi structured interview. Assessments are conducted on a six-point scale (0=not at all to 5=severe)with a total score range of 0-70. A score of &gt;50 is considered to be a moderate-severe intensity.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="11.0"/>
                    <measurement group_id="O2" value="53.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Treatment</title>
          <description>Bilateral high frequency (10Hz) rTMS</description>
        </group>
        <group group_id="E2">
          <title>Sham Treatment</title>
          <description>Sham bilateral rTMS treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Insufficient time period used to be able to establish a substantive therapeutic effect of rTMS; standard dosing method may be inadequate due to volumetric changes in brain regions in schizophrenia; concurrent antipsychotic medication.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Paul Fitzgerald</name_or_title>
      <organization>Monash Alfred Psychiatry Research Centre</organization>
      <phone>+61 3 9076 6564</phone>
      <email>p.fitzgerald@alfred.org.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

